Cambridge Innovation Capital

Cambridge Innovation Capital Limited is a venture capital firm based in Cambridge, United Kingdom, that specializes in early-stage and mid-venture investments. Founded in 2013, the firm focuses on healthcare, life sciences, and technology sectors, particularly in therapeutics, medtech, diagnostics, digital health, and genomics. It aims to support disruptive and deep-tech companies, primarily those emerging from the University of Cambridge and the surrounding innovation cluster. Cambridge Innovation Capital has raised £275 million to date, allowing it to make significant equity investments, up to £19 million, in its portfolio companies. The firm has established itself as a preferred investor within the Cambridge ecosystem, providing it with unique access to high-potential investment opportunities.

Michael Anstey

Partner

Anne Horgan Ph.D

Partner

Edward Inns

Senior Associate

Ian Jauncey

Operating Partner

Ian Lane

Partner

Dipesh Patel

Operating Partner

Rob Sprawson

Partner, CFO and Board Member

Robert Tansley

Partner

Chris Tapper

Senior Associate

73 past transactions

Complement Therapeutics

Series A in 2023
Complement Therapeutics operates as a preclinical stage company. Complement Therapeutics develops a precision medicine diagnostic platform allowing it to stratify patients based on their complement-activation profile with the potential to enable both patient selection and serving as an efficacy biomarker in future clinical studies.

Pretzel Therapeutics

Series A in 2022
Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug development, and company formation. Our name is inspired by the focal point of our science, the mitochondrion, whose highly folded inner membrane is one of many fascinating features that make it unlike any other organelle in the body.

Salience Labs

Seed Round in 2022
Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designed to exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany.

Epitopea

Seed Round in 2022
Epitopea is a transatlantic biotechnology company developing transformational immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. Cryptigen™ TSAs are discovered by a proprietary approach deploying immunopetidomics, mass spectrometry, genomics, and bioinformatics, which allows the identification of conserved, aberrantly-expressed, tumour-specific antigens, hidden in cancer's 'junk' DNA. These hidden Cryptigen™ TSAs have been identified by research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal.

Microbiotica

Series B in 2022
Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. The company specializes in the development of human microbiome-based therapeutics and biomarkers. Its platform is designed to identify gut bacteria associated with specific phenotypes, offering a high level of precision. This capability allows researchers to determine phenotypes before conducting tests on candidate bacteria using advanced in vitro and in vivo models. By focusing on the science of the microbiome, Microbiotica aims to advance the understanding and application of live bacterial therapeutics in clinical settings.

Pretzel Therapeutics

Venture Round in 2021
Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug development, and company formation. Our name is inspired by the focal point of our science, the mitochondrion, whose highly folded inner membrane is one of many fascinating features that make it unlike any other organelle in the body.

PetMedix

Series B in 2021
PetMedix Ltd is a veterinary biopharmaceutical company based in Cambridge, United Kingdom, focused on developing innovative therapeutic drug solutions for pets. Founded in 2017, the company utilizes advanced scientific methods to create transgenic mouse platforms, specifically Ky9 and Felyne, which are designed to produce high-quality therapeutic antibodies tailored for pets. Drawing on over thirty years of expertise in human drug development, PetMedix aims to improve the health and well-being of animals by delivering effective therapies that enhance their quality of life.

CMR Surgical

Series D in 2021
CMR Surgical is to make minimal access surgery available to all. With Versius they have delivered a next-generation tool to fit seamlessly into today’s operating rooms, working in harmony with the surgeon to improve patient outcomes and deliver value for healthcare providers.

Origami

Series C in 2021
Origami Energy Ltd., a technology company, develops and commercializes a technology platform for distributed energy applications. It offers technology and solutions to connect, control, and manage a network of existing energy generating/energy using/energy storing assets connected to the electricity grid. The company was incorporated in 2013 and is based in London, United Kingdom.

Sense Biodetection

Series B in 2021
Sense Biodetection Limited is a molecular diagnostics company based in Abingdon, United Kingdom, established in 2013. The company specializes in creating innovative, user-centered handheld tests aimed at enhancing healthcare decisions and processes, particularly in the areas of infections and oncology. Its flagship product, True Point-of-Care, is designed to provide clinical diagnostic capabilities that facilitate improved treatment and informed decision-making in a decentralized healthcare environment.

Gyroscope Therapeutics

Series C in 2021
Gyroscope is an ophthalmology company developing gene therapies for the treatment of eye diseases linked to an unbalanced complement system. Gyroscope was founded to explore the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD) and gene therapy as a mode of treatment delivery.

Riverlane

Series A in 2021
Riverlane is the most advanced quantum computing software developer

Secondmind

Corporate Round in 2020
Founded in 2016 with a mission to empower people in business to make better decisions, Secondmind - The Decisions Company - is underpinned by years of award-winning, practical artificial intelligence (AI) and machine learning (ML) research, performed by a team of world-class researchers, data scientists and ML engineers. Secondmind closes the gap between people and AI, and supercharges decision-making with the Secondmind Decision Engine, an intuitive and insightful software platform that helps people in industries from supply chain to automotive predict, plan, influence outcomes, manage risk, and make complex decisions with ease and confidence. Secondmind is backed by leading venture funds including Amadeus Capital, Atlantic Bridge, and Cambridge Innovation Capital, among others.

Seldon

Series A in 2020
Seldon Technologies Ltd. is a company based in Shoreditch, United Kingdom, that specializes in open-source machine learning deployment. Founded in 2014, Seldon offers a platform called Seldon Deploy, which facilitates the transition from research and development to production for machine learning engineering teams, achieving efficiency gains of up to 84%. The platform provides essential features such as audit trails, compliance approvals, and detailed model explanations. Seldon's open-source projects are recognized for their excellence in model serving, monitoring, and explanations, with over 2.5 million installations and 250,000 models deployed. The company serves a diverse clientele, including major enterprises in technology, pharmaceuticals, automotive, finance, and retail, and its solutions are integrated with leading machine learning platforms from companies like Google and Red Hat. Seldon has also garnered recognition as a "Cool Vendor" in AI Core technologies by Gartner in 2020.

Congenica

Series C in 2020
Congenica Ltd. is a UK-based company that specializes in clinical data solutions for genetic diagnosis. Founded in 2012, it leverages pioneering research from the Wellcome Trust Sanger Institute and NHS clinicians to develop its flagship product, the Sapientia platform. This clinical genomic analytics tool integrates human DNA sequences with deep clinical phenotyping, allowing clinicians and researchers to interpret genetic diseases effectively. Sapientia supports clinical diagnosis, prognosis, and research, and plays a crucial role in personalized medicine applications, including the creation of disease registries and the identification of patient populations for clinical studies. By providing diagnostic decision support and associated services, Congenica aims to enhance patient care through precise diagnoses and the curation of evolving knowledge bases, ultimately contributing to advancements in clinical trials and drug development.

GeoSpock

Venture Round in 2020
GeoSpock Limited is a spatial big data platform company based in Cambridge, United Kingdom, with additional offices in Tokyo and Singapore. Founded in 2013, it specializes in developing a data indexing platform that provides analytics, visualization, and insights across various scales of data. The company offers products such as GeoSpock DB Discovery and GeoSpock DB Enterprise, which are cloud-based services designed to manage and analyze location-tagged information. These tools facilitate dynamic data fusion and enable users to perform complex queries for performance analytics. GeoSpock's platform can be utilized in a range of applications, from real-time tracking of logistics fleets to optimizing operations in smart cities, helping to uncover hidden patterns and improve decision-making. By harnessing trillions of data points in seconds, GeoSpock aims to transform business operations and contribute to sustainability efforts, such as reducing traffic congestion.

AudioTelligence

Series A in 2020
AudioTelligence Ltd develops a software that pre-processes the sound and solves loud background noise problem that makes it difficult to hear or understand a conversation for humans and voice activated devices. The company delivers real-time audio processing technology for the enhancement of automatic speech recognition (ASR) systems. The company's software transforms the clarity and intelligibility of the audio. The company was founded in 2017 and is based in Cambridge, United Kingdom.

Sense Biodetection

Series A in 2019
Sense Biodetection Limited is a molecular diagnostics company based in Abingdon, United Kingdom, established in 2013. The company specializes in creating innovative, user-centered handheld tests aimed at enhancing healthcare decisions and processes, particularly in the areas of infections and oncology. Its flagship product, True Point-of-Care, is designed to provide clinical diagnostic capabilities that facilitate improved treatment and informed decision-making in a decentralized healthcare environment.

CMR Surgical

Series C in 2019
CMR Surgical is to make minimal access surgery available to all. With Versius they have delivered a next-generation tool to fit seamlessly into today’s operating rooms, working in harmony with the surgeon to improve patient outcomes and deliver value for healthcare providers.

Gyroscope Therapeutics

Series B in 2019
Gyroscope is an ophthalmology company developing gene therapies for the treatment of eye diseases linked to an unbalanced complement system. Gyroscope was founded to explore the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD) and gene therapy as a mode of treatment delivery.

PredictImmune

Series B in 2019
PredictImmune is developing pioneering tools for guiding treatment options in immune-mediated inflammatory diseases with the first product addressing Inflammatory Bowel Disease (both Crohn’s and ulcerative colitis). Based on world-leading research at Cambridge University, UK, they are developing a simple lab test, using a small blood sample, which accurately identifies patients at diagnosis who are at risk of experiencing severe, relapsing disease. These patients are likely to benefit from early biologics therapy. Physicians, patients and payors all recognise the value of such an approach to the management of Inflammatory Bowel Disease.

Riverlane

Seed Round in 2019
Riverlane is the most advanced quantum computing software developer

Audio Analytic

Series B in 2019
Audio Analytic Ltd. specializes in sound recognition software aimed at enhancing the contextual awareness of consumer technology. The company offers a range of products, including its ai3TM analytics software, which classifies and recognizes various sounds, and AuditoryNET, which utilizes a dedicated machine learning pipeline for optimized sound recognition. Their offerings enable devices such as smart speakers, video doorbells, smartphones, and true wireless earbuds to detect and interpret sounds beyond speech and music, contributing to applications in safety, security, wellbeing, health, entertainment, and communication. Established in 2008 and based in Cambridge, UK, with an additional office in San Francisco, Audio Analytic serves original equipment manufacturers and chip providers across multiple industries, including consumer electronics and acoustics.

STORM Therapeutics

Series A in 2019
Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment. Established in 2015, the company aims to create novel therapeutics by targeting pathways involved in RNA modification. Originally known as Iceni Therapeutics Limited, it rebranded to Storm Therapeutics in June 2016. Through its innovative approach, Storm Therapeutics seeks to advance cancer therapeutics by leveraging the role of RNA in cellular processes.

Secondmind

Series B in 2019
Founded in 2016 with a mission to empower people in business to make better decisions, Secondmind - The Decisions Company - is underpinned by years of award-winning, practical artificial intelligence (AI) and machine learning (ML) research, performed by a team of world-class researchers, data scientists and ML engineers. Secondmind closes the gap between people and AI, and supercharges decision-making with the Secondmind Decision Engine, an intuitive and insightful software platform that helps people in industries from supply chain to automotive predict, plan, influence outcomes, manage risk, and make complex decisions with ease and confidence. Secondmind is backed by leading venture funds including Amadeus Capital, Atlantic Bridge, and Cambridge Innovation Capital, among others.

PolyProx

Seed Round in 2019
PolyProx Therapeutics is developer of a novel class of drug intended to provide new therapies for cancer treatment. The company's drug will use novel engineered protein that is able to selectively target tumour cells and trigger natural degradation machinery within the cell, enabling cancer patients to benefit from the treatment that targets and remove disease-causing proteins.

Cytora

Series B in 2019
Cytora transforms underwriting for commercial insurance. The Cytora Risk Engine uses artificial intelligence to learn the patterns of risks over time, enabling insurers to underwrite more efficiently and deliver fairer prices to customers. The company's goal is to raise the insurance industry to a new standard where insurance is fast and built on a foundation of tractable data. The company's products allow insurers to enhance underwriting profitability. Cytora was founded on 2014 and is headquartered in London.

Inivata

Series B in 2019
Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis to improve testing and treatment for oncologists and their patients. Unlike conventional invasive biopsies, Inivata detects and analyses genomic material from a cancer patient’s cell-free, circulating tumour DNA (ctDNA) which can be collected through a simple blood sample. This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored and treated.

Pragmatic Semiconductor

Venture Round in 2019
PragmatIC Semiconductor specializes in the design and manufacture of flexible integrated circuits, known as FlexICs, which are thinner than a human hair and can be embedded in various objects. This technology allows for the creation of innovative solutions that traditional electronics cannot easily achieve. The company's offerings include a range of products such as application-specific FlexICs through its FlexIC Foundry service, as well as standard products like the ConnectIC family, which supports applications like RFID and NFC. PragmatIC's manufacturing process utilizes the FlexLogIC production system, enabling efficient and cost-effective high-volume production. The company serves a diverse clientele across sectors such as consumer goods, packaging, healthcare, and security. Founded in 2006 and based in Cambridge, UK, with an additional facility in Sedgefield, PragmatIC is recognized as a leader in ultra-low-cost flexible electronics.

Imagen

Series B in 2019
Imagen Ltd specializes in media archive management solutions, providing a range of products designed to assist organizations in managing their media assets. Its offerings include Imagen2, a media asset management and publishing system; ImagenCloud, a cloud-based platform for managing and publishing videos and images; and Orbital, a compliance recording system. The company's client roster features notable organizations such as the Ministry of Defence, The Police, the BBC, ITN, the Imperial War Museum, British Telecom, and British Pathe. Founded in 1991 and originally known as Cambridge Imaging Systems Limited, Imagen Ltd rebranded in August 2015. The company is headquartered in Willingham, United Kingdom, and serves a diverse range of industries, enabling content owners to efficiently publish and monetize their media archives.

Morphogen-IX

Series B in 2018
Morphogen-IX Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing novel treatments for pulmonary arterial hypertension (PAH), a serious condition affecting lung blood vessels that can lead to heart failure. Founded in 2015 by Index Ventures, the company is exploring the therapeutic potential of bone morphogenetic proteins (BMPs), particularly BMP9 and BMP10, which have shown promise in enhancing BMPR-II receptor signaling in endothelial cells. This signaling is crucial for reversing the effects of PAH, as compromised BMPR-II signaling is central to the disease's pathology. Current PAH treatments primarily address symptoms, and effective long-term solutions are limited, often requiring risky lung transplants. Morphogen-IX employs a semi-virtual business model, leveraging a network of experienced professionals in drug discovery while maintaining operational efficiency through outsourcing. The company's founders are recognized experts in both PAH and BMP research, positioning Morphogen-IX to potentially transform the treatment landscape for this life-limiting disease.

Bicycle Therapeutics

Series B in 2018
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

CEDAR Audio

Seed Round in 2018
CEDAR Audio is the world's only company dedicated solely to audio restoration and speech enhancement for film, post, TV and radio broadcast, CD and DVD mastering, libraries and archives, and for audio forensic investigation. Established in 1988 following five years of research funded by the British Library National Sound Archive, CEDAR Audio is based in Cambridge, UK, and retains strong academic links with Cambridge University, itself one of the world's leading centres for digital signal processing research. The company currently numbers two Cambridge University Professors and a Director of Studies among its Directors, further strengthening its ability to remain at the forefront of its field. CEDAR Audio is committed to furthering the science and technology of audio restoration and speech enhancements in all its forms. It not only manufactures many of the leading products in these fields, but actively pursues research into new techniques in each of them. The company also places a premium on the highest standards of customer support, and has earned numerous accolades in this area.

AudioTelligence

Seed Round in 2018
AudioTelligence Ltd develops a software that pre-processes the sound and solves loud background noise problem that makes it difficult to hear or understand a conversation for humans and voice activated devices. The company delivers real-time audio processing technology for the enhancement of automatic speech recognition (ASR) systems. The company's software transforms the clarity and intelligibility of the audio. The company was founded in 2017 and is based in Cambridge, United Kingdom.

Bicycle Therapeutics

Series B in 2018
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

Nstream

Series B in 2018
Nstream, formerly known as Swim.Ai, Inc., is a technology company that specializes in advanced analytics software for processing data at the edge of networks. Founded in 2015 and headquartered in San Jose, California, Nstream offers the SWIM EDX platform, which transforms streaming edge data into real-time insights and predictions, addressing the challenges associated with big data. The company serves a diverse clientele, including original equipment manufacturers, service providers, enterprises, cities, and Internet of Things (IoT) vendors. Nstream's solutions integrate edge computing, machine learning, and self-training digital twins within a mesh architecture. Additionally, its Swim Continuum platform enables organizations to build and manage continuous intelligence applications, providing operational decision support and situational awareness through real-time and contextual data analysis. With a focus on enhancing human decision-making, Nstream aims to deliver efficient performance and seamless interoperability with existing enterprise systems.

Undo

Series B in 2018
Undo Ltd. develops innovative debugging tools tailored for software developers, architects, product managers, and application engineers. The company offers a live recorder that captures and replays software execution, enabling users to identify programming errors and debug them effectively. Its flagship product, UndoDB, serves as an interactive reversible debugger specifically for C/C++ on Linux and Android platforms. Undo's technologies are utilized by major software companies across various industries, including data management, networking, electronic design automation, and finance, allowing developers to address complex challenges efficiently. By employing its unique record, rewind, and replay capabilities, Undo helps developers quickly diagnose and resolve issues in both production and testing environments, enhancing productivity and improving software quality. Founded in 2005, Undo is headquartered in Cambridge, United Kingdom, with an additional office in San Francisco, California.

CMR Surgical

Series B in 2018
CMR Surgical is to make minimal access surgery available to all. With Versius they have delivered a next-generation tool to fit seamlessly into today’s operating rooms, working in harmony with the surgeon to improve patient outcomes and deliver value for healthcare providers.

Origami

Series B in 2018
Origami Energy Ltd., a technology company, develops and commercializes a technology platform for distributed energy applications. It offers technology and solutions to connect, control, and manage a network of existing energy generating/energy using/energy storing assets connected to the electricity grid. The company was incorporated in 2013 and is based in London, United Kingdom.

GeoSpock

Series A in 2018
GeoSpock Limited is a spatial big data platform company based in Cambridge, United Kingdom, with additional offices in Tokyo and Singapore. Founded in 2013, it specializes in developing a data indexing platform that provides analytics, visualization, and insights across various scales of data. The company offers products such as GeoSpock DB Discovery and GeoSpock DB Enterprise, which are cloud-based services designed to manage and analyze location-tagged information. These tools facilitate dynamic data fusion and enable users to perform complex queries for performance analytics. GeoSpock's platform can be utilized in a range of applications, from real-time tracking of logistics fleets to optimizing operations in smart cities, helping to uncover hidden patterns and improve decision-making. By harnessing trillions of data points in seconds, GeoSpock aims to transform business operations and contribute to sustainability efforts, such as reducing traffic congestion.

Cytora

Series A in 2017
Cytora transforms underwriting for commercial insurance. The Cytora Risk Engine uses artificial intelligence to learn the patterns of risks over time, enabling insurers to underwrite more efficiently and deliver fairer prices to customers. The company's goal is to raise the insurance industry to a new standard where insurance is fast and built on a foundation of tractable data. The company's products allow insurers to enhance underwriting profitability. Cytora was founded on 2014 and is headquartered in London.

CMR Surgical

Series A in 2017
CMR Surgical is to make minimal access surgery available to all. With Versius they have delivered a next-generation tool to fit seamlessly into today’s operating rooms, working in harmony with the surgeon to improve patient outcomes and deliver value for healthcare providers.

Secondmind

Series A in 2017
Founded in 2016 with a mission to empower people in business to make better decisions, Secondmind - The Decisions Company - is underpinned by years of award-winning, practical artificial intelligence (AI) and machine learning (ML) research, performed by a team of world-class researchers, data scientists and ML engineers. Secondmind closes the gap between people and AI, and supercharges decision-making with the Secondmind Decision Engine, an intuitive and insightful software platform that helps people in industries from supply chain to automotive predict, plan, influence outcomes, manage risk, and make complex decisions with ease and confidence. Secondmind is backed by leading venture funds including Amadeus Capital, Atlantic Bridge, and Cambridge Innovation Capital, among others.

Z Factor

Series A in 2017
Z Factor Limited is a drug discovery company founded in 2015 to identify and develop therapeutic agents to treat alpha-1-antitrypsin deficiency. The company was created by Index Ventures in partnership with the University of Cambridge.

Congenica

Series B in 2017
Congenica Ltd. is a UK-based company that specializes in clinical data solutions for genetic diagnosis. Founded in 2012, it leverages pioneering research from the Wellcome Trust Sanger Institute and NHS clinicians to develop its flagship product, the Sapientia platform. This clinical genomic analytics tool integrates human DNA sequences with deep clinical phenotyping, allowing clinicians and researchers to interpret genetic diseases effectively. Sapientia supports clinical diagnosis, prognosis, and research, and plays a crucial role in personalized medicine applications, including the creation of disease registries and the identification of patient populations for clinical studies. By providing diagnostic decision support and associated services, Congenica aims to enhance patient care through precise diagnoses and the curation of evolving knowledge bases, ultimately contributing to advancements in clinical trials and drug development.

Audio Analytic

Series A in 2017
Audio Analytic Ltd. specializes in sound recognition software aimed at enhancing the contextual awareness of consumer technology. The company offers a range of products, including its ai3TM analytics software, which classifies and recognizes various sounds, and AuditoryNET, which utilizes a dedicated machine learning pipeline for optimized sound recognition. Their offerings enable devices such as smart speakers, video doorbells, smartphones, and true wireless earbuds to detect and interpret sounds beyond speech and music, contributing to applications in safety, security, wellbeing, health, entertainment, and communication. Established in 2008 and based in Cambridge, UK, with an additional office in San Francisco, Audio Analytic serves original equipment manufacturers and chip providers across multiple industries, including consumer electronics and acoustics.

Exvastat

Seed Round in 2017
Exvastat is a preclinical-stage pharmaceutical company established in 2016, focused on developing a treatment for acute respiratory distress syndrome (ARDS) using a repurposed drug already available for other medical indications. The company aims to address the significant mortality and debilitating complications associated with ARDS by inhibiting vascular leaks that contribute to pulmonary edema. By improving patient outcomes, Exvastat also seeks to lower the financial burden on healthcare providers caring for critically ill patients.

Microbiotica

Seed Round in 2016
Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. The company specializes in the development of human microbiome-based therapeutics and biomarkers. Its platform is designed to identify gut bacteria associated with specific phenotypes, offering a high level of precision. This capability allows researchers to determine phenotypes before conducting tests on candidate bacteria using advanced in vitro and in vivo models. By focusing on the science of the microbiome, Microbiotica aims to advance the understanding and application of live bacterial therapeutics in clinical settings.

Imagen

Venture Round in 2016
Imagen Ltd specializes in media archive management solutions, providing a range of products designed to assist organizations in managing their media assets. Its offerings include Imagen2, a media asset management and publishing system; ImagenCloud, a cloud-based platform for managing and publishing videos and images; and Orbital, a compliance recording system. The company's client roster features notable organizations such as the Ministry of Defence, The Police, the BBC, ITN, the Imperial War Museum, British Telecom, and British Pathe. Founded in 1991 and originally known as Cambridge Imaging Systems Limited, Imagen Ltd rebranded in August 2015. The company is headquartered in Willingham, United Kingdom, and serves a diverse range of industries, enabling content owners to efficiently publish and monetize their media archives.

Undo

Series A in 2016
Undo Ltd. develops innovative debugging tools tailored for software developers, architects, product managers, and application engineers. The company offers a live recorder that captures and replays software execution, enabling users to identify programming errors and debug them effectively. Its flagship product, UndoDB, serves as an interactive reversible debugger specifically for C/C++ on Linux and Android platforms. Undo's technologies are utilized by major software companies across various industries, including data management, networking, electronic design automation, and finance, allowing developers to address complex challenges efficiently. By employing its unique record, rewind, and replay capabilities, Undo helps developers quickly diagnose and resolve issues in both production and testing environments, enhancing productivity and improving software quality. Founded in 2005, Undo is headquartered in Cambridge, United Kingdom, with an additional office in San Francisco, California.

Pragmatic Semiconductor

Venture Round in 2016
PragmatIC Semiconductor specializes in the design and manufacture of flexible integrated circuits, known as FlexICs, which are thinner than a human hair and can be embedded in various objects. This technology allows for the creation of innovative solutions that traditional electronics cannot easily achieve. The company's offerings include a range of products such as application-specific FlexICs through its FlexIC Foundry service, as well as standard products like the ConnectIC family, which supports applications like RFID and NFC. PragmatIC's manufacturing process utilizes the FlexLogIC production system, enabling efficient and cost-effective high-volume production. The company serves a diverse clientele across sectors such as consumer goods, packaging, healthcare, and security. Founded in 2006 and based in Cambridge, UK, with an additional facility in Sedgefield, PragmatIC is recognized as a leader in ultra-low-cost flexible electronics.

Carrick Therapeutics

Series A in 2016
Carrick Therapeutics, Ltd., founded in 2015 and based in Dublin, Ireland, focuses on developing innovative cancer therapeutics aimed at transforming cancer treatment. The company targets specific molecular pathways associated with aggressive and resistant cancer forms, allowing for early detection of predictive biomarkers. This approach facilitates timely treatment initiation for patients, enhancing the potential for improved outcomes in cancer care.

PervasID

Series A in 2016
PervasID is developing a high reliability, wide area passive RFID system with the potential to provide location capability based on the EPC Class1 Gen2 standard. Spun out from research activity in the Engineering Department at the University of Cambridge, the technology is now successfully deployed in several field trials.

Fluidic Analytics

Series B in 2016
Fluidic Analytics Limited designs, develops, and manufactures equipment for the characterization of proteins in laboratory, medical, and consumer applications. The company provides Fluidity One, a product that enables in-solution sizing and quantification of native protein. The company also offers Fluidity One-W, a product that enables high sensitivity in-solution analysis of protein size and protein interaction kinetics. Its products are used for applications, including protein quality, interactions, aggregation, and sizing. The company serves scientists, clinics, and healthcare providers. Fluidic Analytics Limited was founded in 2013 and is based in Cambridge, United Kingdom.

CMR Surgical

Series A in 2016
CMR Surgical is to make minimal access surgery available to all. With Versius they have delivered a next-generation tool to fit seamlessly into today’s operating rooms, working in harmony with the surgeon to improve patient outcomes and deliver value for healthcare providers.

STORM Therapeutics

Series A in 2016
Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment. Established in 2015, the company aims to create novel therapeutics by targeting pathways involved in RNA modification. Originally known as Iceni Therapeutics Limited, it rebranded to Storm Therapeutics in June 2016. Through its innovative approach, Storm Therapeutics seeks to advance cancer therapeutics by leveraging the role of RNA in cellular processes.

Origami

Series A in 2016
Origami Energy Ltd., a technology company, develops and commercializes a technology platform for distributed energy applications. It offers technology and solutions to connect, control, and manage a network of existing energy generating/energy using/energy storing assets connected to the electricity grid. The company was incorporated in 2013 and is based in London, United Kingdom.

Audio Analytic

Venture Round in 2016
Audio Analytic Ltd. specializes in sound recognition software aimed at enhancing the contextual awareness of consumer technology. The company offers a range of products, including its ai3TM analytics software, which classifies and recognizes various sounds, and AuditoryNET, which utilizes a dedicated machine learning pipeline for optimized sound recognition. Their offerings enable devices such as smart speakers, video doorbells, smartphones, and true wireless earbuds to detect and interpret sounds beyond speech and music, contributing to applications in safety, security, wellbeing, health, entertainment, and communication. Established in 2008 and based in Cambridge, UK, with an additional office in San Francisco, Audio Analytic serves original equipment manufacturers and chip providers across multiple industries, including consumer electronics and acoustics.

Inivata

Series A in 2016
Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis to improve testing and treatment for oncologists and their patients. Unlike conventional invasive biopsies, Inivata detects and analyses genomic material from a cancer patient’s cell-free, circulating tumour DNA (ctDNA) which can be collected through a simple blood sample. This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored and treated.

Morphogen-IX

Series A in 2016
Morphogen-IX Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing novel treatments for pulmonary arterial hypertension (PAH), a serious condition affecting lung blood vessels that can lead to heart failure. Founded in 2015 by Index Ventures, the company is exploring the therapeutic potential of bone morphogenetic proteins (BMPs), particularly BMP9 and BMP10, which have shown promise in enhancing BMPR-II receptor signaling in endothelial cells. This signaling is crucial for reversing the effects of PAH, as compromised BMPR-II signaling is central to the disease's pathology. Current PAH treatments primarily address symptoms, and effective long-term solutions are limited, often requiring risky lung transplants. Morphogen-IX employs a semi-virtual business model, leveraging a network of experienced professionals in drug discovery while maintaining operational efficiency through outsourcing. The company's founders are recognized experts in both PAH and BMP research, positioning Morphogen-IX to potentially transform the treatment landscape for this life-limiting disease.

Jukedeck

Venture Round in 2015
Jukedeck Limited is a London-based company that specializes in creating soundtracks for videos through artificial intelligence. Established in 2012, the company has developed technology that composes and adapts personalized music for various contexts, allowing users to generate original music autonomously. Jukedeck also offers an API that grants access to a library of royalty-free music, enabling users to create, browse, and edit their own soundtracks. This innovative approach utilizes deep neural networks to understand and facilitate music composition, enhancing creative processes for users. As of July 2019, Jukedeck operates as a subsidiary of Bytedance UK Limited.

GeoSpock

Series A in 2015
GeoSpock Limited is a spatial big data platform company based in Cambridge, United Kingdom, with additional offices in Tokyo and Singapore. Founded in 2013, it specializes in developing a data indexing platform that provides analytics, visualization, and insights across various scales of data. The company offers products such as GeoSpock DB Discovery and GeoSpock DB Enterprise, which are cloud-based services designed to manage and analyze location-tagged information. These tools facilitate dynamic data fusion and enable users to perform complex queries for performance analytics. GeoSpock's platform can be utilized in a range of applications, from real-time tracking of logistics fleets to optimizing operations in smart cities, helping to uncover hidden patterns and improve decision-making. By harnessing trillions of data points in seconds, GeoSpock aims to transform business operations and contribute to sustainability efforts, such as reducing traffic congestion.

STORM Therapeutics

Seed Round in 2015
Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment. Established in 2015, the company aims to create novel therapeutics by targeting pathways involved in RNA modification. Originally known as Iceni Therapeutics Limited, it rebranded to Storm Therapeutics in June 2016. Through its innovative approach, Storm Therapeutics seeks to advance cancer therapeutics by leveraging the role of RNA in cellular processes.

Imagen

Series A in 2015
Imagen Ltd specializes in media archive management solutions, providing a range of products designed to assist organizations in managing their media assets. Its offerings include Imagen2, a media asset management and publishing system; ImagenCloud, a cloud-based platform for managing and publishing videos and images; and Orbital, a compliance recording system. The company's client roster features notable organizations such as the Ministry of Defence, The Police, the BBC, ITN, the Imperial War Museum, British Telecom, and British Pathe. Founded in 1991 and originally known as Cambridge Imaging Systems Limited, Imagen Ltd rebranded in August 2015. The company is headquartered in Willingham, United Kingdom, and serves a diverse range of industries, enabling content owners to efficiently publish and monetize their media archives.

Abcodia

Series B in 2015
Abcodia Ltd. engages in the discovery and validation of molecular biomarkers for disease diagnosis and screening. It offers Roca Test solutions for early ovarian cancer detection to customers in Arizona, Illinois, Massachusetts, New Jersey, Texas, Georgia, Michigan, Missouri, North Carolina, Nevada, Ohio, Oregon, Virginia, Washington, Wisconsin, the District of Columbia, and the United Kingdom. The company was incorporated in 2010 and is based in London, United Kingdom.

Undo

Venture Round in 2015
Undo Ltd. develops innovative debugging tools tailored for software developers, architects, product managers, and application engineers. The company offers a live recorder that captures and replays software execution, enabling users to identify programming errors and debug them effectively. Its flagship product, UndoDB, serves as an interactive reversible debugger specifically for C/C++ on Linux and Android platforms. Undo's technologies are utilized by major software companies across various industries, including data management, networking, electronic design automation, and finance, allowing developers to address complex challenges efficiently. By employing its unique record, rewind, and replay capabilities, Undo helps developers quickly diagnose and resolve issues in both production and testing environments, enhancing productivity and improving software quality. Founded in 2005, Undo is headquartered in Cambridge, United Kingdom, with an additional office in San Francisco, California.

Congenica

Series A in 2015
Congenica Ltd. is a UK-based company that specializes in clinical data solutions for genetic diagnosis. Founded in 2012, it leverages pioneering research from the Wellcome Trust Sanger Institute and NHS clinicians to develop its flagship product, the Sapientia platform. This clinical genomic analytics tool integrates human DNA sequences with deep clinical phenotyping, allowing clinicians and researchers to interpret genetic diseases effectively. Sapientia supports clinical diagnosis, prognosis, and research, and plays a crucial role in personalized medicine applications, including the creation of disease registries and the identification of patient populations for clinical studies. By providing diagnostic decision support and associated services, Congenica aims to enhance patient care through precise diagnoses and the curation of evolving knowledge bases, ultimately contributing to advancements in clinical trials and drug development.

Pragmatic Semiconductor

Venture Round in 2015
PragmatIC Semiconductor specializes in the design and manufacture of flexible integrated circuits, known as FlexICs, which are thinner than a human hair and can be embedded in various objects. This technology allows for the creation of innovative solutions that traditional electronics cannot easily achieve. The company's offerings include a range of products such as application-specific FlexICs through its FlexIC Foundry service, as well as standard products like the ConnectIC family, which supports applications like RFID and NFC. PragmatIC's manufacturing process utilizes the FlexLogIC production system, enabling efficient and cost-effective high-volume production. The company serves a diverse clientele across sectors such as consumer goods, packaging, healthcare, and security. Founded in 2006 and based in Cambridge, UK, with an additional facility in Sedgefield, PragmatIC is recognized as a leader in ultra-low-cost flexible electronics.

Inivata

Venture Round in 2014
Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis to improve testing and treatment for oncologists and their patients. Unlike conventional invasive biopsies, Inivata detects and analyses genomic material from a cancer patient’s cell-free, circulating tumour DNA (ctDNA) which can be collected through a simple blood sample. This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored and treated.

Jukedeck

Seed Round in 2014
Jukedeck Limited is a London-based company that specializes in creating soundtracks for videos through artificial intelligence. Established in 2012, the company has developed technology that composes and adapts personalized music for various contexts, allowing users to generate original music autonomously. Jukedeck also offers an API that grants access to a library of royalty-free music, enabling users to create, browse, and edit their own soundtracks. This innovative approach utilizes deep neural networks to understand and facilitate music composition, enhancing creative processes for users. As of July 2019, Jukedeck operates as a subsidiary of Bytedance UK Limited.

Origami

Venture Round in 2014
Origami Energy Ltd., a technology company, develops and commercializes a technology platform for distributed energy applications. It offers technology and solutions to connect, control, and manage a network of existing energy generating/energy using/energy storing assets connected to the electricity grid. The company was incorporated in 2013 and is based in London, United Kingdom.

Imagen

Series A in 2014
Imagen Ltd specializes in media archive management solutions, providing a range of products designed to assist organizations in managing their media assets. Its offerings include Imagen2, a media asset management and publishing system; ImagenCloud, a cloud-based platform for managing and publishing videos and images; and Orbital, a compliance recording system. The company's client roster features notable organizations such as the Ministry of Defence, The Police, the BBC, ITN, the Imperial War Museum, British Telecom, and British Pathe. Founded in 1991 and originally known as Cambridge Imaging Systems Limited, Imagen Ltd rebranded in August 2015. The company is headquartered in Willingham, United Kingdom, and serves a diverse range of industries, enabling content owners to efficiently publish and monetize their media archives.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.